Suppr超能文献

一个全面的严重急性呼吸综合征冠状病毒2-人类蛋白质-蛋白质相互作用组网络确定了2019冠状病毒病的病理生物学和宿主靶向疗法。

A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19.

作者信息

Zhou Yadi, Liu Yuan, Gupta Shagun, Paramo Mauricio I, Hou Yuan, Mao Chengsheng, Luo Yuan, Judd Julius, Wierbowski Shayne, Bertolotti Marta, Nerkar Mriganka, Jehi Lara, Drayman Nir, Nicolaescu Vlad, Gula Haley, Tay Savaş, Randall Glenn, Lis John T, Feschotte Cédric, Erzurum Serpil C, Cheng Feixiong, Yu Haiyuan

机构信息

Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, US.

Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY 14853, US.

出版信息

Res Sq. 2022 Jun 7:rs.3.rs-1354127. doi: 10.21203/rs.3.rs-1354127/v2.

Abstract

Physical interactions between viral and host proteins are responsible for almost all aspects of the viral life cycle and the host's immune response. Studying viral-host protein-protein interactions is thus crucial for identifying strategies for treatment and prevention of viral infection. Here, we use high-throughput yeast two-hybrid and affinity purification followed by mass spectrometry to generate a comprehensive SARS-CoV-2-human protein-protein interactome network consisting of both binary and co-complex interactions. We report a total of 739 high-confidence interactions, showing the highest overlap of interaction partners among published datasets as well as the highest overlap with genes differentially expressed in samples (such as upper airway and bronchial epithelial cells) from patients with SARS-CoV-2 infection. Showcasing the utility of our network, we describe a novel interaction between the viral accessory protein ORF3a and the host zinc finger transcription factor ZNF579 to illustrate a SARS-CoV-2 factor mediating a direct impact on host transcription. Leveraging our interactome, we performed network-based drug screens for over 2,900 FDA-approved/investigational drugs and obtained a curated list of 23 drugs that had significant network proximities to SARS-CoV-2 host factors, one of which, carvedilol, showed promising antiviral properties. We performed electronic health record-based validation using two independent large-scale, longitudinal COVID-19 patient databases and found that carvedilol usage was associated with a significantly lowered probability (17%-20%, < 0.001) of obtaining a SARS-CoV-2 positive test after adjusting various confounding factors. Carvedilol additionally showed anti-viral activity against SARS-CoV-2 in a human lung epithelial cell line [half maximal effective concentration (EC ) value of 4.1 µM], suggesting a mechanism for its beneficial effect in COVID-19. Our study demonstrates the value of large-scale network systems biology approaches for extracting biological insight from complex biological processes.

摘要

病毒与宿主蛋白之间的物理相互作用几乎负责病毒生命周期和宿主免疫反应的所有方面。因此,研究病毒-宿主蛋白-蛋白相互作用对于确定治疗和预防病毒感染的策略至关重要。在这里,我们使用高通量酵母双杂交和亲和纯化后进行质谱分析,以生成一个由二元和共复合体相互作用组成的全面的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)-人类蛋白-蛋白相互作用组网络。我们报告了总共739个高置信度相互作用,显示出已发表数据集中相互作用伙伴的最高重叠率,以及与SARS-CoV-2感染患者样本(如上呼吸道和支气管上皮细胞)中差异表达基因的最高重叠率。为了展示我们网络的实用性,我们描述了病毒辅助蛋白ORF3a与宿主锌指转录因子ZNF579之间的一种新型相互作用,以说明一种对宿主转录有直接影响的SARS-CoV-2因子。利用我们的相互作用组,我们对2900多种美国食品药品监督管理局(FDA)批准/正在研究的药物进行了基于网络的药物筛选,并获得了一份精心挑选的23种药物清单,这些药物与SARS-CoV-2宿主因子具有显著的网络接近性,其中一种药物卡维地洛显示出有前景的抗病毒特性。我们使用两个独立的大规模纵向2019冠状病毒病(COVID-19)患者数据库进行了基于电子健康记录的验证,发现使用卡维地洛与在调整各种混杂因素后获得SARS-CoV-2阳性检测结果的概率显著降低(17%-20%,<0.001)相关。卡维地洛在人肺上皮细胞系中还显示出对SARS-CoV-2的抗病毒活性[半数最大效应浓度(EC )值为4.1µM],这表明了其在COVID-19中发挥有益作用的机制。我们的研究证明了大规模网络系统生物学方法对于从复杂生物过程中提取生物学见解的价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7507/9176654/5b35ede21987/nihpp-rs1354127v2-f0005.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验